SynthesisFrontiers in endocrinology2025
Risk factors and early prediction of pancreatic cancer among patients with diabetes mellitus: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Performance of risk prediction models for pancreatic cancer in patients with new-onset diabetes: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Article
- Diabetes mellitus, ABO Blood groups, and biochemical correlates in pancreatic cancer- A retrospective study from Jeddah.Journal of family medicine and primary care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Diabetes mellitus (DM) increases the risk of pancreatic cancer (PC). This study evaluates risk factors for PC in DM patients and the predictive accuracy of machine learning (ML) models to provide research-backed data for the development and update of intelligent prediction tools. Methods: PubMed, Cochrane, Embase, and Web of Science were systematically retrieved, up to December 1, 2024. The quality of the original studies was assessed through the Newcastle-Ottawa Scale (NOS). A meta-analysis was conducted on the c-index that reflects the comprehensive accuracy of the prediction models. Results: 18 studies were included. The rough annual incidence of PC among DM was estimated at 0.4% (95% CI: 0.1% - 0.9%), and the incidence rates of PC for new-onset DM and pre-existing DM were 0.3% (95% CI: 0.1% - 0.5%) and 0.5% (95% CI: 0% - 2.7%), respectively. The possible risk factors included age at DM diagnosis, weight changes, blood sugar, ALP, GI symptoms, pancreatic disease history, and the usage of hypoglycemic drugs. ML models based on risk factors had ROC-AUCs of 0.79 (95% CI: 0.75-0.84) in the training set and 0.79 (95% CI: 0.71-0.87) in the validation set. Conclusions: Risk factors for PC in DM are diverse. Current ML models appear to exhibit favorable predictive accuracy but are built on severely imbalanced data. Future studies with larger, broader populations are needed to address this limitation. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42025631534.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.